Back to top
more

Capricor Therapeutics (CAPR)

(Delayed Data from NSDQ)

$28.38 USD

28.38
3,094,982

+0.43 (1.54%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $28.69 +0.31 (1.09%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 29% (175 out of 247)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Capricor (CAPR) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Capricor (CAPR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Capricor Therapeutics (CAPR) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Capricor (CAPR) delivered earnings and revenue surprises of 7.14% and 279.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

AdaptHealth Corp. (AHCO) Q2 Earnings and Revenues Miss Estimates

by Zacks Equity Research

AdaptHealth Corp. (AHCO) delivered earnings and revenue surprises of -35.71% and 0.17%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ICU Medical (ICUI) Q2 Earnings and Revenues Lag Estimates

by Zacks Equity Research

ICU Medical (ICUI) delivered earnings and revenue surprises of -18.93% and 1.39%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Canopy Growth Corporation (CGC) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Canopy Growth Corporation (CGC) delivered earnings and revenue surprises of -250% and 0.02%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Sanghamitra Saha headshot

Forget Bargains, Play 5 Stocks With Rising P/E Instead

by Sanghamitra Saha

Forget undervalued stocks, there is room for upside even in stocks with rising P/E.

Zacks Equity Research

Here's Why Capricor (CAPR) is Poised for a Turnaround After Losing 19.3% in 4 Weeks

by Zacks Equity Research

Capricor (CAPR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks Equity Research

Capricor Therapeutics (CAPR) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Capricor (CAPR) delivered earnings and revenue surprises of 22.73% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Strength Seen in Capricor (CAPR): Can Its 5.7% Jump Turn into More Strength?

by Zacks Equity Research

Capricor (CAPR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Capricor Therapeutics (CAPR) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

by Zacks Equity Research

Capricor (CAPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.